PROCHIEVE 4% to Prevent Endometrial Hyperplasia
|
We are providing PROCHIEVE 4% (progesterone gel) for a third-party study evaluating the long-term effects of Hormone Replacement Therapy in menopausal women. The study investigators selected PROCHIEVE 4% as the progesterone product to prevent endometrial hyperplasia in all menopausal women with an intact uterus who receive estrogen in the study. The study was initiated in 2004, and is expected to last five years.
[Return to Research and Development Pipeline]
|
|